Table 2.
Differential diagnosis between COVID-19-related pneumonitis and drugs (ICI or TKI)-related pneumonitis: clinical (A) and radiological (B) characteristics
| (A) Main clinical characteristic | (B) Main radiological characteristics | ||||||
|---|---|---|---|---|---|---|---|
| COVID-19 | ICI | TKI | COVID-19 | ICI | TKI | ||
| Dyspnea | X | X | X | GG areas | X | X | X |
| Cough | X | X | X | Consolidations | - | X | X |
| Chest pain | X | X | X | Septal thickening | X | X | X |
| Fever | X | X | X | Traction bronchiectasis | - | X | X |
| Hypoxiemia | X | X | X | Features of AIP/ILD | X | X | |
| Myalgia | X | -* | - |
Multifocal manifestations: • > Peripheral • > Lower lobe • > Subpleural |
X - X X |
X X X - |
X X X - |
| Fatigue | X | - | - | ||||
| Headache | X | - | - | ||||
| Anosmia | X | - | - | ||||
| Dysgeusia | X | - | - | Bilateral manifestations | X | X | X |
| Abdominal pain | X | -* | - | Vascular thickening | X | - | - |
| Diarrhea | X | -* | -* | Small centrilobular nodules | - | - | X |
| Runny nose | X | - | - | Honeycombing | - | - | X |
COVID-19 coronavirus disease 2019, ICI immune checkpoint inhibitor, TKI tyrosine kinase inhibitor, GG ground glass, AIP acute interstitial pneumonitis, ILD interstitial lung disease
*As a further immune-related adverse event